Trials / Conditions / Metastatic Bladder Cancer

Metastatic Bladder Cancer

12 registered clinical trials studyying Metastatic Bladder Cancer — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessmen NCT06138561	Dana-Farber Cancer Institute	—
Unknown	Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic NCT05259319	Centre Georges Francois Leclerc	Phase 1
Terminated	Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy T NCT04887831	G1 Therapeutics, Inc.	Phase 2
Active Not Recruiting	A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing NCT06129084	Bernie Eigl	—
Completed	A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Adva NCT04200963	Ikena Oncology	Phase 1
Terminated	A Window of Opportunity Trial: Avelumab in Non-metastatic Muscle Invasive Bladder Cancer NCT03498196	Baylor College of Medicine	Phase 1 / Phase 2
Completed	Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carci NCT03430895	Memorial Sloan Kettering Cancer Center	Phase 2
Active Not Recruiting	A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Blad NCT02989584	Memorial Sloan Kettering Cancer Center	Phase 1 / Phase 2
Completed	Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies NCT02030067	Processa Pharmaceuticals	Phase 1 / Phase 2
Unknown	The Association Between Alpha 1 Acid Glycoprotein Level and Outcome Metastatic Cancer Treated With Docetaxel NCT01814150	Gottfried Maya	—
Completed	Phase I / II Study of Enadenotucirev by Sub-acute Fractionated IV Dosing in Cancer Patients NCT02028442	Akamis Bio	Phase 1 / Phase 2
Completed	A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer NCT01454089	Achieve Life Sciences	Phase 2